EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Inhaled Corticosteroid-Long-Acting Beta-2 Agonist Fixed-Dose Combinations: Preferred Controller in 6- to 11-Year-Olds with Persistent Asthma

Gizem Koken, Sinem Polat Terece, Ceren Varer Akpinar, Hacer Ilbilge Ertoy Karagol, Arzu Bakirtas

International Archives of Allergy and Immunology · 2025

DOI: 10.1159/000544938 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2025. Verfasst von Gizem Koken und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Allergy, Gazi University Faculty of Medicine, Ankara, Turkey, kokengizem@gmail.com. Hauptthemen laut MEDLINE: Asthma, Adrenergic beta-2 Receptor Agonists, Adrenal Cortex Hormones, Anti-Asthmatic Agents. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

So far, there is no direct comparison between inhaled corticosteroid (ICS) monotherapy and ICS-long-acting beta-2 agonists (LABA) fixed-dose combination therapies in 6- to 11-year-old children with persistent asthma. The primary objective of this study was to compare ICS monotherapy and ICS-LABA fixed-dose combination therapies for the frequency of exacerbations requiring systemic corticosteroids (CS).

Methods

Patients aged 6–11 years diagnosed with persistent asthma during steps 2–4 of treatment, prescribed daily ICS-containing treatment (fluticasone propionate [FP], fluticasone propionate/salmeterol [FP/SAL], and budesonide/formoterol [BUD/F]), and followed for at least 1 year at our institution from January 2021 to January 2024 were included. The hospital’s electronic database was used to retrospectively record asthma controller medication, frequency of asthma exacerbations (including those requiring systemic CS, emergency department [ED] visit and/or hospitalization) and pneumonia.

Results

The frequency of all exacerbations, exacerbations requiring systemic CS, and exacerbations requiring ED visit/hospitalization were significantly higher in the FP group compared to the FP/SAL and BUD/F groups (p < 0.001, p = 0.003, p < 0.001, respectively). There were no significant differences between the FP/SAL and BUD/F groups concerning all exacerbation parameters (p > 0.05). The incidence of pneumonia was very low in the fixed-dose combination groups, making a statistical comparison unfeasible.

Conclusion

ICS-LABA fixed-dose combination therapies have been found to be more effective than ICS monotherapy in preventing asthma exacerbations in 6–11-year-old children with persistent asthma and could be recommended as the preferred controllers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAdrenergic beta-2 Receptor AgonistsAdrenal Cortex HormonesAnti-Asthmatic AgentsHumansChildFemaleAdministration, InhalationMaleRetrospective StudiesDrug CombinationsTreatment OutcomeDrug Therapy, Combination

Stichwörter der Autor:innen

ChildrenFixed-dose combination therapiesInhaled corticosteroidsLong-acting beta-2 agonistsPersistent asthma

Substanzen

Adrenergic beta-2 Receptor AgonistsAdrenal Cortex HormonesAnti-Asthmatic AgentsDrug Combinations

Autor:innen und Institutionen

  • Department of Pediatric Allergy, Gazi University Faculty of Medicine, Ankara, Turkey, kokengizem@gmail.com.
  • Department of Pediatric Allergy, Gazi University Faculty of Medicine, Ankara, Turkey.
  • Department of Public Health, Giresun University Faculty of Medicine, Giresun, Turkey.

Zitieren

APA

Koken, G., Terece, S. P., Akpinar, C. V., Ertoy Karagol, H. I., & Bakirtas, A. (2025). Inhaled Corticosteroid-Long-Acting Beta-2 Agonist Fixed-Dose Combinations: Preferred Controller in 6- to 11-Year-Olds with Persistent Asthma. International Archives of Allergy and Immunology. https://doi.org/10.1159/000544938

Vancouver

Koken G, Terece SP, Akpinar CV, Ertoy Karagol HI, Bakirtas A. Inhaled Corticosteroid-Long-Acting Beta-2 Agonist Fixed-Dose Combinations: Preferred Controller in 6- to 11-Year-Olds with Persistent Asthma. International Archives of Allergy and Immunology. 2025. doi:10.1159/000544938

BibTeX
@article{Koken2025,
  author = {Koken, Gizem and Terece, Sinem Polat and Akpinar, Ceren Varer and Ertoy Karagol, Hacer Ilbilge and Bakirtas, Arzu},
  title = {Inhaled Corticosteroid-Long-Acting Beta-2 Agonist Fixed-Dose Combinations: Preferred Controller in 6- to 11-Year-Olds with Persistent Asthma},
  journal = {International Archives of Allergy and Immunology},
  year = {2025},
  doi = {10.1159/000544938}
}
Kostenlos starten →